Journal
TRENDS IN IMMUNOLOGY
Volume 32, Issue 5, Pages 232-239Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2011.02.007
Keywords
-
Categories
Funding
- NHLBI NIH HHS [P01 HL103453] Funding Source: Medline
- NIAID NIH HHS [T32 AI089474] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007250] Funding Source: Medline
- NINDS NIH HHS [R01 NS071996-02, R01 NS071996] Funding Source: Medline
Ask authors/readers for more resources
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Experimental autoimmune encephalomyelitis (EAE) is widely used to dissect molecular mechanisms of MS and to develop new therapeutic strategies. The T helper 17 (Th17) subset of CD4 T cells plays a crucial role in the development of EAE. IL-17, a cytokine produced by Th17 cells, participates in EAE pathogenesis through induction of inflammatory gene expression in target cells. Recent work has shown that Act1, a U-box E3 ubiquitin ligase, is recruited to IL-17 receptor (IL-17R) upon IL-17 stimulation and is required for IL-17-mediated signaling. Here, we review the molecular and cellular mechanisms by which IL-17 and Act1-mediated signaling contribute to EAE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available